查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2132267

美國介入性腫瘤手術市場規模、佔有率和趨勢分析報告：按方法、手術、癌症類型、最終用途和細分市場預測（2026-2033 年）

U.S. Interventional Oncology Procedures Market Size, Share & Trends Analysis Report By Technique, By Procedures, By Cancer Type, By End-use, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

美國介入性腫瘤手術市場概覽

預計到 2025 年，美國介入性腫瘤手術市場價值將達到 108 億美元，到 2026 年將成長到 120 億美元，到 2033 年將達到 234 億美元，2026 年至 2033 年的複合年成長率為 9.9%。

人們認為，這種成長是由於癌症發病率上升、微創手術的進步、老年人口的成長、對早期癌症檢測的日益重視以及公共和私人對介入腫瘤學投資的增加所致。

隨著全球癌症患者數量的急劇成長，對更先進解決方案的需求日益迫切，以提供更有效的癌症治療。介入性腫瘤學中微創技術的進步正在改變癌症治療，使更精準、更具標靶性的治療成為可能。先進的消融系統在這項變革中發揮著至關重要的作用，因為它們能夠更有效地摧毀腫瘤，同時最大限度地減少對周圍組織的影響。將可控且可重複的熱能輸送到腫瘤（尤其是在骨骼和軟組織中）的能力，正在提高介入性腫瘤學手術的可靠性。例如，2022年9月，史賽克公司的OptaBlate骨腫瘤消融系統獲得了FDA的批准。這項介入性腫瘤學技術採用了取得專利的微注射技術，能夠實現更快、更穩定的消融，並允許同時治療兩個椎體節段。 OptaBlate為患有疼痛性轉移性腫瘤的患者提供了可靠的治療選擇。這些技術進步正在縮短患者的康復時間，並為通常副作用顯著的全身性治療提供了替代方案。因此，介入性腫瘤學正逐漸成為轉移性癌症患者的首選治療方案，既能改善疼痛管理，也能提高整體治療效果。

近年來，由於微波消融、冷凍消融、不可逆電穿孔（IRE）和放射性栓塞等技術相較於傳統手術具有諸多優勢，例如住院時間更短、併發症更少，其應用顯著擴展。微波消融系統尤其因其加熱迅速、消融範圍廣以及對高血管化腫瘤的高效性而備受青睞。 2024年7月，IceCure Medical宣布其配備CryoProbes的新一代XSense冷凍消融系統已獲得美國食品藥物管理局（FDA）的批准。這項微創技術旨在透過可控冷凍來破壞腫瘤，凸顯了冷凍消融技術在介入性腫瘤學領域的持續進步，為外科腫瘤切除術提供了一種替代方案。這些進步使得臨床醫生能夠在門診或一日內完成手術，從而提高患者的便利性並降低醫療成本。

此外，老年人口的成長進一步推動了美國介入性腫瘤治療市場的發展，這主要是由於老年族群癌症發生率較高。隨著老齡化，長期暴露於致癌性、基因突變累積以及免疫功能減弱都會顯著增加罹癌風險，從而推動了對微創癌症治療的需求。例如，到2023年，美國65歲及以上人口將達到約5,980萬，擴大了符合介入性腫瘤治療條件的患者族群。同樣，2024年3月，美國疾病管制與預防中心（CDC）透過全國性的宣傳活動，強調了定期癌症篩檢的重要性，該活動重點關注乳癌、大腸癌、子宮頸癌和肺癌。 CDC強調，定期篩檢和早期診斷能夠提高治療效果和存活率，從而進一步促進標靶治療和微創癌症治療的臨床應用。因此，大眾對癌症症狀和預防醫學的認知不斷提高，預計在預測期內，介入性腫瘤手術的數量將會增加。

預計公共和私人對介入腫瘤學的投資增加將透過研究、創新和基礎設施擴張進一步加速市場成長。例如，2024年12月，介入放射學會（SIR）基金會向四個研究計畫津貼150萬美元，其中兩個計畫專注於介入性腫瘤學。一項研究旨在建立一種新的肝細胞癌（HCC）模型，另一項研究則致力於利用基因分型為HCC的精準介入治療制定指南。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章：美國介入性腫瘤手術市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 美國介入性腫瘤手術市場分析工具

第4章：美國介入性腫瘤手術市場：依手術類型分類的估計與趨勢分析

  • 美國介入性腫瘤市場：按手術類型分類的趨勢分析
  • 美國介入性腫瘤手術市場：依方法分類，展望
  • 市場規模、預測與趨勢分析，2021-2033年
  • 消融療法
  • 栓塞治療
  • 切片檢查技術
  • 標靶治療遞送系統
  • 影像引導技術不佳

第5章：美國介入性腫瘤手術市場：依手術類型分類的估計與趨勢分析

  • 美國介入性腫瘤手術市場：按手術類型分類的趨勢分析
  • 美國介入性腫瘤手術市場：依手術類型分類，展望
  • 市場規模、預測與趨勢分析，2021-2033年
  • 腫瘤消融
  • 腫瘤切片檢查
  • 血管介入
  • 安寧療護

第6章：美國介入性腫瘤手術市場：按癌症類型分類的估計和趨勢分析

  • 美國介入性腫瘤學市場：按癌症類型分類的趨勢分析
  • 美國介入性腫瘤市場：按癌症類型分類，展望
  • 市場規模、預測與趨勢分析，2021-2033年
  • 肝癌
  • 肺癌
  • 腎癌
  • 攝護腺癌
  • 其他

第7章：美國介入性腫瘤手術市場：依最終用途分類的估算與趨勢分析

  • 美國介入性腫瘤手術市場：按最終用途分類的趨勢分析
  • 美國介入性腫瘤手術市場：按最終用途分類的展望
  • 市場規模、預測與趨勢分析，2021-2033年
  • 醫院
  • 門診手術中心
  • 其他

第8章 競爭情勢

  • 參與企業的分類
  • 主要公司簡介
    • Medtronic
    • Boston Scientific Corporation
    • Johnson & Johnson MedTech
    • Cook Medical
    • AngioDynamics Inc.
    • Stryker Corporation
    • Terumo Corporation
    • Siemens Healthineers AG
    • Baxter International Inc.
    • Becton, Dickinson and Company
    • B. Braun
    • GE Healthcare
Product Code: GVR-4-68040-947-0

U.S. Interventional Oncology Procedures Market Summary

The U.S. interventional oncology procedures market size was valued at USD 10.8 billion in 2025 and is projected to grow from USD 12.0 billion in 2026 to USD 23.4 billion by 2033, at a CAGR of 9.9% from 2026 to 2033. This growth can be attributed to the increasing prevalence of cancer, rising technological advancements in minimally invasive procedures, growing geriatric population, increasing focus on early cancer detection, and growing public and private investments in the field of interventional oncology.

There is a significant rise in the number of cancer cases globally, which drives the need for advanced solutions to facilitate better cancer care. The growing advancements of minimally invasive techniques in interventional oncology are reshaping cancer treatment by enabling more precise and targeted therapies. Advanced ablation systems are playing a crucial role in this shift, as they allow for more effective tumor destruction with minimal impact on surrounding tissues. The ability to deliver controlled, repeatable thermal energy to tumors, particularly in bone and soft tissues, has enhanced the reliability of interventional oncology procedures. For instance, in September 2022, Stryker's OptaBlate bone tumor ablation system received FDA clearance. This interventional oncology technology features patented micro-infusion technology, enabling quicker, more consistent ablations and the simultaneous treatment of two vertebral body levels. OptaBlate offers a reliable solution for patients with painful metastatic tumors. These technological improvements reduce patient recovery time and offer an alternative to systemic treatments, which often have significant side effects. As a result, interventional oncology is becoming an increasingly preferred option for patients with metastatic cancers, improving both pain management and overall outcomes.

The adoption of microwave ablation, cryoablation, irreversible electroporation (IRE), and radioembolization has expanded significantly in recent years due to their ability to treat tumors with shorter hospital stays and fewer complications than conventional surgery. In particular, microwave ablation systems are gaining preference because they provide faster heating, larger ablation zones, and improved efficacy in highly vascular tumors. In July 2024, IceCure Medical announced that the U.S. FDA granted regulatory clearance for its next-generation XSense cryoablation system with CryoProbes. The minimally invasive technology is intended to destroy tumors through controlled freezing and offers an alternative to surgical tumor removal, highlighting continued advancements in cryoablation technologies within interventional oncology. These advancements are helping clinicians perform outpatient or same-day procedures, thereby improving patient convenience and reducing healthcare costs.

Moreover, the growing geriatric population is further driving the growth of the U.S. interventional oncology procedures industry, primarily due to the higher incidence of cancer among older adults. As age increases, prolonged exposure to carcinogens, the accumulation of genetic mutations, and declining immune function significantly elevate the risk of cancer development, leading to greater demand for minimally invasive cancer treatments. For instance, the U.S. population aged 65 years and older reached approximately 59.8 million in 2023, expanding the pool of patients eligible for interventional oncology procedures. Similarly, in March 2024, the U.S. Centers for Disease Control and Prevention (CDC) emphasized the importance of routine cancer screening programs through its national awareness initiatives focused on breast, colorectal, cervical, and lung cancers. The organization highlighted that regular screening and early diagnosis improve treatment effectiveness and survival outcomes, further supporting the growing clinical adoption of targeted and minimally invasive oncology therapies. Increasing public awareness regarding cancer symptoms and preventive healthcare is therefore expected to contribute to higher procedural volumes in the interventional oncology market over the forecast period.

Increasing public and private investments in interventional oncology will further accelerating the market growth by expanding research, innovation, and infrastructure. For instance, in December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million in grants to four research projects, two of which focus on interventional oncology. One study will develop a novel model of hepatocellular carcinoma (HCC), and the other will use genetic subtyping to guide precision interventions for HCC.

U.S. Interventional Oncology Procedures Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the U.S. interventional oncology procedures market report based on technique, procedure, cancer type, and end-use:

  • Technique Outlook (Revenue, USD Billion, 2021 - 2033)
  • Ablation Therapies
  • Embolization Therapies
  • Biopsy Techniques
  • Targeted Therapy Delivery Systems
  • Image-Guided Procedures
  • Procedures Outlook (Revenue, USD Billion, 2021 - 2033)
  • Tumor Ablation
  • Tumor Biopsy
  • Vascular Interventions
  • Palliative Care
  • Cancer Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Liver Cancer
  • Lung Cancer
  • Kidney
  • Prostate cancer
  • Others
  • End-use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technique
    • 1.2.2. Procedure
    • 1.2.3. Cancer Type
    • 1.2.4. End Use
    • 1.2.5. Country scope
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technique outlook
    • 2.2.2. Procedure outlook
    • 2.2.3. Cancer Type outlook
    • 2.2.4. End Use outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Interventional Oncology Procedures Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. U.S. Interventional Oncology Procedures Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. U.S. Interventional Oncology Procedures Market: Technique Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Interventional Oncology Procedures Market: Technique Movement Analysis
  • 4.3. U.S. Interventional Oncology Procedures Market by Technique Outlook (USD Billion)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.5. Ablation Therapies
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.6. Embolization Therapies
    • 4.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.7. Biopsy Techniques
    • 4.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.8. Targeted Therapy Delivery Systems
    • 4.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.9. Image-Guided Procedures
    • 4.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Interventional Oncology Procedures Market: Procedure Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Interventional Oncology Procedures Market: Procedure Movement Analysis
  • 5.3. U.S. Interventional Oncology Procedures Market by Procedure Outlook (USD Billion)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Tumor Ablation
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.6. Tumor Biopsy
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.7. Vascular Interventions
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.8. Palliative Care
    • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. U.S. Interventional Oncology Procedures Market: Cancer Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Interventional Oncology Procedures Market: Cancer Type Movement Analysis
  • 6.3. U.S. Interventional Oncology Procedures Market by Cancer Type Outlook (USD Billion)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Liver Cancer
    • 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6. Lung Cancer
    • 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.7. Kidney
    • 6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.8. Prostate cancer
    • 6.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.9. Others
    • 6.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. U.S. Interventional Oncology Procedures Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Interventional Oncology Procedures Market: End-Use Movement Analysis
  • 7.3. U.S. Interventional Oncology Procedures Market by End Use Outlook (USD Billion)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Hospitals
    • 7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Ambulatory Surgical Centers
    • 7.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Others
    • 7.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Key Company Profiles
    • 8.2.1. Medtronic
      • 8.2.1.1. Company Overview
      • 8.2.1.2. Financial Performance
      • 8.2.1.3. Product/Service Benchmarking
      • 8.2.1.4. Strategic Initiatives
    • 8.2.2. Boston Scientific Corporation
      • 8.2.2.1. Company Overview
      • 8.2.2.2. Financial Performance
      • 8.2.2.3. Product/Service Benchmarking
      • 8.2.2.4. Strategic Initiatives
    • 8.2.3. Johnson & Johnson MedTech
      • 8.2.3.1. Company Overview
      • 8.2.3.2. Financial Performance
      • 8.2.3.3. Product/Service Benchmarking
      • 8.2.3.4. Strategic Initiatives
    • 8.2.4. Cook Medical
      • 8.2.4.1. Company Overview
      • 8.2.4.2. Financial Performance
      • 8.2.4.3. Product/Service Benchmarking
      • 8.2.4.4. Strategic Initiatives
    • 8.2.5. AngioDynamics Inc.
      • 8.2.5.1. Company Overview
      • 8.2.5.2. Financial Performance
      • 8.2.5.3. Product/Service Benchmarking
      • 8.2.5.4. Strategic Initiatives
    • 8.2.6. Stryker Corporation
      • 8.2.6.1. Company Overview
      • 8.2.6.2. Financial Performance
      • 8.2.6.3. Product/Service Benchmarking
      • 8.2.6.4. Strategic Initiatives
    • 8.2.7. Terumo Corporation
      • 8.2.7.1. Company Overview
      • 8.2.7.2. Financial Performance
      • 8.2.7.3. Product/Service Benchmarking
      • 8.2.7.4. Strategic Initiatives
    • 8.2.8. Siemens Healthineers AG
      • 8.2.8.1. Company Overview
      • 8.2.8.2. Financial Performance
      • 8.2.8.3. Product/Service Benchmarking
      • 8.2.8.4. Strategic Initiatives
    • 8.2.9. Baxter International Inc.
      • 8.2.9.1. Company Overview
      • 8.2.9.2. Financial Performance
      • 8.2.9.3. Product/Service Benchmarking
      • 8.2.9.4. Strategic Initiatives
    • 8.2.10. Becton, Dickinson and Company
      • 8.2.10.1. Company Overview
      • 8.2.10.2. Financial Performance
      • 8.2.10.3. Product/Service Benchmarking
      • 8.2.10.4. Strategic Initiatives
    • 8.2.11. B. Braun
      • 8.2.11.1. Company Overview
      • 8.2.11.2. Financial Performance
      • 8.2.11.3. Product/Service Benchmarking
      • 8.2.11.4. Strategic Initiatives
    • 8.2.12. GE Healthcare
      • 8.2.12.1. Company Overview
      • 8.2.12.2. Financial Performance
      • 8.2.12.3. Product/Service Benchmarking
      • 8.2.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. interventional oncology procedures market, by technique, 2021 - 2033 (USD Billion)
  • Table 4 U.S. interventional oncology procedures market, by procedure, 2021 - 2033 (USD Billion)
  • Table 5 U.S. interventional oncology procedures market, by cancer type, 2021 - 2033 (USD Billion)
  • Table 6 U.S. interventional oncology procedures market, by end use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 U.S. interventional oncology procedures market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Technique & procedure outlook (USD Billion)
  • Fig. 10 Camcer type & end use outlook (USD Billion)
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. interventional oncology procedures market dynamics
  • Fig. 13 U.S. interventional oncology procedures market: Porter's five forces analysis
  • Fig. 14 U.S. interventional oncology procedures market: PESTLE analysis
  • Fig. 15 U.S. interventional oncology procedures market: Technique segment dashboard
  • Fig. 16 U.S. interventional oncology procedures market: Technique market share analysis, 2025 & 2033
  • Fig. 17 Ablation therapies market, 2021 - 2033 (USD Billion)
  • Fig. 18 Embolization therapies market, 2021 - 2033 (USD Billion)
  • Fig. 19 Biopsy techniques market, 2021 - 2033 (USD Billion)
  • Fig. 20 Targeted therapy Delivery Systems market, 2021 - 2033 (USD Billion)
  • Fig. 21 Image-guided procedures market, 2021 - 2033 (USD Billion)
  • Fig. 22 U.S. interventional oncology procedures market: Procedure segment dashboard
  • Fig. 23 U.S. interventional oncology procedures market: Procedure market share analysis, 2025 & 2033
  • Fig. 24 Tumor ablation market, 2021 - 2033 (USD Billion)
  • Fig. 25 Tumor biopsy market, 2021 - 2033 (USD Billion)
  • Fig. 26 Vascular interventions market, 2021 - 2033 (USD Billion)
  • Fig. 27 Palliative care market, 2021 - 2033 (USD Billion)
  • Fig. 28 U.S. interventional oncology procedures market: Cancer type segment dashboard
  • Fig. 29 U.S. interventional oncology procedures market: Cancer type market share analysis, 2025 & 2033
  • Fig. 30 Liver Cancer market, 2021 - 2033 (USD Billion)
  • Fig. 31 Lung Cancer market, 2021 - 2033 (USD Billion)
  • Fig. 32 Kidney market, 2021 - 2033 (USD Billion)
  • Fig. 33 Prostate cancer market, 2021 - 2033 (USD Billion)
  • Fig. 34 Others market, 2021 - 2033 (USD Billion)
  • Fig. 35 U.S. interventional oncology procedures market: End use segment dashboard
  • Fig. 36 U.S. interventional oncology procedures market: End use market share analysis, 2025 & 2033
  • Fig. 37 Hospitals market, 2021 - 2033 (USD Billion)
  • Fig. 38 Ambulatory surgical centers market, 2021 - 2033 (USD Billion)
  • Fig. 39 Others market, 2021 - 2033 (USD Billion)
  • Fig. 40 Company categorization
  • Fig. 41 Company market position analysis
  • Fig. 42 Strategic framework